first_imgArgentina star Sergio Aguero is hoping to return for Manchester City in their Barclays Premier League clash against Liverpool tomorrow.The prolific striker has missed City’s last seven games after suffering a hamstring injury while on international duty.A comeback for the 27-year-old – who scored five goals against Newcastle on his last City appearance – would be timely with fellow forward Wilfried Bony doubtful with a hamstring problem.Aguero told the club’s website: “I do hope I can play in this game. I’m doing everything in my power to get to the match in top condition. It’s been a frustrating time.”Ivory Coast international Bony was sidelined during the recent international break after being forced off early during City’s goalless draw at Aston Villa on November 8.Playmaker David Silva could also be nearing a return after a seven-game absence with a knee injury but Samir Nasri looks set to be out until February with a hamstring problem.Saturday’s encounter against Jurgen Klopp’s Liverpool at the Etihad Stadium will see City come up against their former midfielder James Milner, who left the club for Anfield in the summer.Aguero said: “He’s a great player, though it will be odd to see him wearing another team’s colours.”He is a true professional and I’m sure he’s going to come against us with everything he’s got.”It should be a great game. Jurgen Klopp has come in and he’s a great addition to the Premier League.”last_img read more

first_imgFOOTBALL: The soccer fraternity in Donegal will be casting a watchful eye on proceedings at the Aviva Stadium tomorrow evening for the FAI Intermediate Cup final between Letterkenny Rovers and Crumlin United FC. However, one club will have more interest than most. Keadue Rovers will see three of its former players take centre stage tomorrow.Liam O’Donnell will man the touchline alongside Eamon Mc Conigley at the Aviva, while Paul ‘The Yank’ Boyle and Mark Forker will be at the spine of the side.John Francis Doogan told Donegal Daily, “Keadue Rovers have loaned THREE key men to the “wee rovers”  and would like to wish them well for their FAI Intermediate Cup Final on Saturday.Liam “Keadue” O’Donnell, Mark Forker and Paul ‘The Yank’ Boyle all received their footballing education at our legendary club, and all at Keadue Rovers are excited for them and are hopeful they will join the list of Keadue Rovers players who have won intermediate cups at Fanad United.”! Indeed it’s exciting times for the Rosses club now with a new pitch about to begin construction.The club will be launching a 100+ club in the next few weeks and would appreciate all help in fundraising to deliver this fantastic facility to the people of West Donegal and firmly establish ourselves as a giant of Donegal football again.FAMOUS DONEGAL CLUB HOPE THEIR ‘LOAN’ STARS PERFORM WELL AT THE AVIVA was last modified: May 13th, 2016 by Mark ForkerShare this:Click to share on Facebook (Opens in new window)Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Reddit (Opens in new window)Click to share on Pocket (Opens in new window)Click to share on Telegram (Opens in new window)Click to share on WhatsApp (Opens in new window)Click to share on Skype (Opens in new window)Click to print (Opens in new window) Tags:AvivaKeadue Rovers FCLoannewsSportStarslast_img read more

first_imgNext StepsMost doctors are moving to decreasing the use of cranial radiation for T-cell leukemia as late side effects can occur after cranial radiation. Late side effects include changes in cognitive abilities, learning disabilities, neuroendocrine changes, and development of secondary malignancy. The next step will be for clinicians to examine the implications and benefits that may accrue when using nelarabine in chemotherapy protocols without cranial radiation. -Overall, 90.2% of patients treated in this trial lived at least four years, and 84.3% had no sign of cancer at four years. -In the group of patients with T-ALL who had increased risk of recurrence, 88.9% of those who received nelarabine were leukemia-free at four years compared to 83.3% of those not treated with nelarabine. -While patients with T-LL did not benefit from the addition of nelarabine, more than 85% lived for four years without signs of disease. -Contrary to results from previous, smaller trials, patients with T-ALL who received escalating doses of methotrexate did better than those who received high-dose methotrexate (four-year disease-free survival with escalating dose was 89.8% vs. 78% with high-dose). -Among T-ALL patients randomly assigned to receive both nelarabine and escalating doses of methotrexate, 92.2% were leukemia-free at four years. -Patients who did not have cancer remission following the initial (induction) phase of chemotherapy were assigned to receive high-dose methotrexate and nelarabine; 54.8% of survived four years without signs of the disease. This is a significant improvement, as historically only about 20% of people with T-ALL who did not experience cancer remission lived another three years, according to the authors. May 17 2018ASCO Perspective”As oncologists, we are constantly striving for better care and outcomes for our patients, even in cancers where survival rates are relatively high compared with others. We now know it’s possible to significantly boost survival in children and young adults with rare forms of leukemia and lymphoma, without introducing additional harsh side effects that can impair their quality of life,” said ASCO President Bruce E. Johnson, MD, FASCO.In a federally funded, randomized phase III clinical trial performed by the Children’s Oncology Group (COG), 90% of children and young adults with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LL) were alive four years after starting treatment regimens on this trial, and 84% were cancer free. These are the highest survival rates for these T-cell malignancies reported to date, according to the authors.The addition of nelarabine (Arranon) to standard chemotherapy provided further benefit for the group of patients with moderate or high risk of T-ALL recurrence — at four years 89% of those who received nelarabine were leukemia-free vs. 83% of those who did not. The study will be presented at the upcoming 2018 ASCO Annual Meeting in Chicago.”T-cell ALL is a disease that requires the use of a very intense and complex chemotherapy regimen. Historically, about 80% of people live at least four years after being treated for their disease, but we felt we could and must do better,” said lead study author Kimberly Dunsmore, MD, professor, Virginia Tech Carilion School of Medicine in Roanoke. “Our trial shows that we could further increase survival rates by about 10%, which is very encouraging.”About the StudyThe trial, begun in 2007, enrolled patients 1-30 years of age with either T-ALL (94% of trial participants) or T-LL (6% of participants). With 1,895 patients, this is the largest randomized clinical trial ever performed in these diseases.The trial had four arms, with all patients receiving the standard, complex, multi-drug chemotherapy regimen known as COG augmented Berlin-Frankfurt-Munster (aBFM) chemotherapy. In addition to receiving aBFM, patients were randomly assigned to also receive either high-dose methotrexate (a chemotherapy) in a hospital or escalating dose methotrexate (a regimen that starts with low doses of methotrexate, gradually increased over time) in an outpatient setting.Related StoriesExciting study shows how centrioles center the process of cell divisionNew curriculum to improve soft skills in schools boosts children’s health and behaviorNANOLIVE‘s novel CX-A defines a new standard for live cell imaging in 96 well plates for continuous organelle monitoring in cell populationsThe group of patients with moderate or high risk of cancer recurrence were also randomly assigned to receive or not receive nelarabine, in addition to chemotherapy, and cranial radiation (to prevent or treat brain metastases).Nelarabine was approved in 2005 by the FDA for the treatment of people with T-ALL and T-LL that had progressed after at least two chemotherapy regimens. Unlike the trials that led to the FDA approval, nelarabine was tested in newly diagnosed patients in this trial.Key Findingscenter_img Source:https://www.asco.org/about-asco/press-center/news-releases/new-regimens-improve-survival-children-and-young-adults-t-celllast_img read more